Lunesta vs Belsomra: What the Real-World Evidence Actually Shows for Women

How These Two Drugs Work Differently in a Woman's Brain

Lunesta and Belsomra target sleep through opposite mechanisms. Lunesta forces your brain into sleep by amplifying the inhibitory neurotransmitter GABA. Belsomra does something quieter: it blocks orexin, the wakefulness signal, and simply lets sleep occur naturally. That distinction matters more than most prescribers discuss.

Lunesta's GABA mechanism and why it hits women harder

Eszopiclone binds to GABA-A receptor complexes, producing sedation within 15 to 30 minutes. The issue is that women clear eszopiclone more slowly than men. When the FDA reviewed pharmacokinetic data in 2013, it found that women have plasma concentrations of eszopiclone approximately 45% higher than men at the same 3 mg dose, which is why the FDA's 2014 label revision specifically lowered the recommended starting dose for women to 1 mg and capped the maximum at 2 mg in most women. This is sex-specific pharmacokinetics in action.

Belsomra's orexin pathway and female hormonal context

Suvorexant blocks OX1R and OX2R orexin receptors equally. Orexin neurons are concentrated in the lateral hypothalamus and are influenced by estrogen. During perimenopause, when estrogen fluctuates and hot flashes fragment sleep, orexin activity is thought to rise, which may explain why dual orexin receptor antagonists show particular promise in menopausal sleep disturbance. Large controlled trials in perimenopausal women specifically remain sparse, and this benefit is partly extrapolated from mechanistic data rather than direct randomized study in that population.

Efficacy: What the Landmark Trials Measured

Both drugs reduce subjective sleep onset latency and increase total sleep time, but the trial designs differed enough that a direct apples-to-apples comparison is difficult.

The Lunesta (eszopiclone) phase 3 data

Krystal et al. (Sleep, 2003) conducted a six-month randomized, double-blind, placebo-controlled trial of eszopiclone 3 mg in 308 adults with chronic insomnia. The drug reduced subjective sleep-onset latency by a mean of 15.5 minutes versus placebo, and increased sleep time by approximately 57 minutes over the 6-month period. Critically, no tolerance to the sleep-maintenance benefit was observed across 6 months. This was a meaningful finding in 2003 because prior z-drugs were only studied short-term. Women made up a slight majority of the sample, but sex-stratified efficacy data were not reported, which is a meaningful evidence gap.

The Belsomra (suvorexant) phase 3 data

Herring et al. (Lancet Neurology, 2014) ran two identically designed 3-month randomized controlled trials across 1,021 adults comparing suvorexant 40 mg, 20 mg, and placebo. Suvorexant at 20 mg reduced subjective sleep-onset latency by 8.4 minutes versus placebo at month 1, and improved wake after sleep onset by 28 minutes. Again, women were enrolled in roughly equal proportions, but sex-stratified subgroup analyses were not the primary focus of the published results. One 12-month open-label extension confirmed no evidence of tolerance development.

Head-to-head data: does any exist?

No large published randomized controlled trial has directly compared eszopiclone with suvorexant head-to-head. Real-world comparative effectiveness studies are emerging, but most are retrospective database analyses with small sample sizes and limited control for confounders such as hormonal contraceptive use or menopausal status. A 2022 retrospective cohort from a Japanese health insurance database found comparable rates of 90-day treatment continuation between suvorexant and z-drugs, with suvorexant showing modestly lower rates of fall-related emergency visits among women over 60. The evidence base is thinner than marketing suggests, and any clinician who tells you one drug is definitively better overall is overstating the data.

Real-World Performance: Side Effects Women Actually Report

Next-morning impairment

This is where the sex difference is starkest. At 3 mg, eszopiclone produces measurable next-morning psychomotor impairment, which is why the FDA added a driving warning to the Lunesta label in 2014. At the FDA-recommended 1 mg starting dose for women, impairment risk drops substantially but does not disappear entirely. Suvorexant at 10 mg carries a much lower next-morning residual sedation signal, though women taking 20 mg should still avoid driving within 8 hours. If your schedule involves early-morning driving, a school run, or operating machinery, the pharmacokinetic profile of suvorexant is clinically preferable at standard doses.

Metallic or bitter taste

A reported metallic or bitter taste affects up to 34% of eszopiclone users and is one of the most common reasons women discontinue Lunesta. This effect is dose-dependent. Suvorexant does not carry this side effect.

Next-day anxiety and mood effects

Some women report a low-grade next-day anxiety or emotional blunting with eszopiclone, particularly during the luteal phase of the menstrual cycle, when GABA receptor sensitivity shifts. This is not documented in large trial data but is a consistent pattern in clinical practice and warrants attention. No equivalent signal exists for suvorexant.

Dependency and withdrawal

Both drugs are Schedule IV controlled substances, but their dependency profiles differ. Eszopiclone produces physiological dependence with continued use, and abrupt discontinuation can cause rebound insomnia, anxiety, and rarely seizures. The Herring trial found no rebound insomnia on discontinuation of suvorexant. Long-term safety data now extend to 12 months for suvorexant without evidence of physiological dependence, which makes it the preferred option for women who anticipate needing sleep support for more than 4 to 6 weeks.

Parasomnias

Complex sleep behaviors including sleepwalking, sleep-driving, and sleep-eating have been documented with both drugs. The FDA added a boxed warning to all sedative-hypnotics, including eszopiclone and suvorexant, for these behaviors in 2019. If you or a family member have ever experienced a parasomnia on any sleep medication, neither drug is appropriate without specialist review.

Sex-Specific Physiology: How Your Hormones Change What These Drugs Do

Menstrual cycle effects

GABA-A receptor sensitivity fluctuates across the menstrual cycle. In the late luteal phase, when progesterone (and its neurosteroid metabolite allopregnanolone) drops, GABA sensitivity changes, which may alter how well eszopiclone works and how much sedation you experience. Women with premenstrual dysphoric disorder (PMDD) or severe PMS often report worse sleep in the luteal phase and may notice their eszopiclone dose feels less effective or causes more morning sedation at different times of the month. Suvorexant's mechanism is independent of GABAergic tone, so it may be more consistent across the cycle, though no controlled trial has directly tested this.

PCOS

Women with polycystic ovary syndrome have a two- to threefold higher prevalence of obstructive sleep apnea (OSA) than age- and weight-matched controls without PCOS. Both eszopiclone and suvorexant can worsen OSA by reducing upper airway muscle tone or reducing arousals that protect the airway. OSA screening before initiating either drug is clinically important in women with PCOS. Suvorexant may have a slightly more favorable respiratory profile in mild OSA based on limited data, but neither drug should be used in moderate-to-severe untreated OSA.

Perimenopause and postmenopause

Sleep disruption affects up to 60% of perimenopausal women, driven by vasomotor symptoms, cortisol dysregulation, and altered orexin signaling. The Menopause Society notes that sleep disturbance is among the most treatment-resistant symptoms of perimenopause. Menopausal hormone therapy (MHT) remains the first-line approach to sleep disruption driven by hot flashes, per The Menopause Society 2023 position statement. Pharmacotherapy for insomnia is typically considered when MHT is insufficient, contraindicated, or declined.

For perimenopausal women needing pharmacotherapy for insomnia, a reasonable clinical framework is:

1. Rule out primary sleep disorders (OSA, restless legs syndrome) before prescribing any hypnotic.
2. Start with cognitive behavioral therapy for insomnia (CBT-I), which has durable benefit without drug risks and is recommended as first-line by ACOG Committee Opinion.
3. If pharmacotherapy is needed short-term: Suvorexant 10 mg is generally preferred over eszopiclone in perimenopause given its lower next-morning impairment profile, absence of rebound insomnia, and theoretical alignment with orexin dysregulation in menopause.
4. If vasomotor symptoms are the primary sleep disruptor: Address the vasomotor symptoms first with MHT or an evidence-based alternative (low-dose fezolinetant 45 mg daily, per the 2023 FDA approval, or low-dose paroxetine 7.5 mg).
5. Reserve eszopiclone for women who have failed suvorexant, need faster sleep-onset effect at a low dose, or have specific cost constraints.

Postpartum and lactation

Neither drug is appropriate postpartum in a breastfeeding woman. Eszopiclone is excreted into human breast milk; levels in infant serum are not well-characterized but are potentially clinically significant given the drug's CNS activity. Suvorexant's transfer into breast milk has not been adequately studied. The clinical guidance is to avoid both. Short-term melatonin or behavioral sleep interventions are the preferred approach in the postpartum period. See the full pregnancy and lactation section below for complete guidance.

Pregnancy and Lactation Safety (Required Reading Before You Fill This Prescription)

Neither eszopiclone nor suvorexant should be used during pregnancy or while breastfeeding. This is not a soft recommendation.

Eszopiclone in pregnancy

Eszopiclone was classified as FDA Pregnancy Category C under the old system, meaning animal reproduction studies showed adverse effects and no adequate well-controlled studies in pregnant women existed. Under the current PLLR labeling system, the Lunesta prescribing information states that neonatal CNS depression and withdrawal have been documented with sedative-hypnotic use near delivery, and that use in the third trimester specifically carries risk of neonatal respiratory depression. Women who become pregnant while on eszopiclone should contact their provider immediately to discuss a tapering plan rather than stopping abruptly, which carries its own risks.

Suvorexant in pregnancy

The Belsomra prescribing information notes no adequate human data on use in pregnancy. Animal studies at high doses showed decreased fetal body weight. The drug should be discontinued if pregnancy is confirmed. Because suvorexant does not carry the same neonatal respiratory depression signal as GABA-acting sedatives, the acute delivery risk may differ, but "no adequate human data" means exactly that.

Lactation

Eszopiclone is present in human milk. Suvorexant has no published human milk data. The recommendation is to avoid both. If you are breastfeeding and experiencing severe insomnia that is impairing function, discuss CBT-I, short-term low-dose melatonin (LactMed entry shows low transfer), or doxylamine-B6 with your provider.

Contraception requirement

Neither drug is a teratogen requiring mandatory contraception in the same legal sense as isotretinoin or valproate, but given the absence of safety data and the documented risks of sedative-hypnotics near delivery, women of reproductive age who are sexually active and not using reliable contraception should discuss pregnancy planning before starting either drug.

Who Each Drug Is Right For (and Who Should Avoid It)

Lunesta (eszopiclone) may fit better if you:

• Need sleep quickly (works well within 15 to 30 minutes at lower doses)
• Have tried suvorexant and found it insufficient for sleep-onset problems
• Are postmenopausal with no OSA and no early-morning driving requirements
• Are comfortable with a 4-to-6-week treatment window and a supervised taper plan
• Have insurance that covers it at low copay (generic eszopiclone is widely available and inexpensive)

Lunesta is NOT appropriate if you:

• Are pregnant, may become pregnant, or are breastfeeding
• Have a history of sleepwalking or any parasomnia
• Have moderate-to-severe OSA
• Drive early in the morning (especially at 2 mg or 3 mg)
• Have a personal or family history of substance use disorder

Belsomra (suvorexant) may fit better if you:

• Have both sleep-onset and sleep-maintenance problems
• Are in perimenopause with fragmented sleep not fully controlled by MHT
• Have PCOS with suspected or mild OSA (discuss with a sleep specialist first)
• Need sleep support beyond 4 to 6 weeks
• Experienced dependence or rebound insomnia on prior z-drugs or benzodiazepines
• Drive early and need the lowest possible next-morning sedation risk at standard doses

Belsomra is NOT appropriate if you:

• Are pregnant, may become pregnant, or are breastfeeding
• Have narcolepsy (contraindicated: blocking orexin in narcolepsy worsens the condition)
• Take strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin), which can double suvorexant plasma levels
• Have moderate-to-severe OSA

Switching From Lunesta to Belsomra: A Practical Guide

Switching is common and generally safe when done correctly. Reasons women switch include persistent metallic taste on eszopiclone, next-morning grogginess, concern about long-term dependence, or a provider's decision to de-prescribe GABA-acting sedatives.

Taper, don't stop

Do not stop eszopiclone abruptly before starting suvorexant. A typical taper reduces the eszopiclone dose by 0.5 mg every 1 to 2 weeks, depending on how long you have been on the drug. Rebound insomnia during the taper is expected and does not mean suvorexant will fail.

Overlap timing

Some clinicians initiate suvorexant at 10 mg on the same night the eszopiclone dose is reduced to 1 mg, though no formal protocol for this transition has been validated in a randomized trial. The goal is to avoid a gap in sleep support during the dose-reduction window.

What to expect in the first two weeks on Belsomra

Suvorexant's effect can feel subtler than eszopiclone. You may not feel "hit by sedation" the way a GABA agonist produces. Sleep onset may take a few nights to feel natural. Clinical trial data show the full efficacy of suvorexant on wake after sleep onset typically emerges by week 2 of treatment. Give it at least 14 nights before concluding it is not working.

Cost and access considerations

Generic eszopiclone costs roughly $15 to $30 for a 30-day supply at major pharmacies without insurance. Suvorexant remains branded (Belsomra) with no generic as of early 2025, and retail cost is $350 to $400 per month without coverage. GoodRx and manufacturer programs can reduce this, but cost is a real barrier. Discuss this with your prescriber before switching.

Conditions That Overlap With Insomnia in Women

Sleep problems in women rarely exist in isolation. Before accepting a long-term hypnotic prescription, a comprehensive approach should screen for:

• Perimenopause and menopause: Vasomotor symptoms disrupt sleep architecture. Treating the underlying hormonal cause often reduces or eliminates the need for a sleep drug.
• Thyroid dysfunction: Both hypothyroidism and hyperthyroidism alter sleep. A TSH level is a reasonable baseline check in any woman presenting with new insomnia.
• Anxiety and depression: These are the most common comorbid conditions with chronic insomnia in women. CBT-I addresses both simultaneously with durable results.
• Restless legs syndrome (RLS): More common in women, particularly during pregnancy, and often misdiagnosed as insomnia. A sleep diary and iron panel (ferritin below 50 ng/mL is a treatment target in RLS) are low-cost first steps.
• PCOS: As noted above, the sleep apnea risk is elevated. A home sleep test or in-lab polysomnography should precede any hypnotic in a woman with PCOS and unexplained fatigue.
• Postpartum thyroiditis: Insomnia in the postpartum period can reflect this condition, which affects 5% to 10% of postpartum women and is frequently missed.